公开(公告)号：US10201507B2

公开(公告)日：2019-02-12

申请号：US14443154

申请日：2013-11-15

申请人： NEUROCHLORE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE AIX MARSEILLE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE BREST

发明人： Yehezkel Ben-Ari ,  Eric Lemonnier ,  Nail Burnashev ,  Roman Tyzio

IPC分类号： A61K38/00 ,  A61K47/00 ,  A61K31/00 ,  A61K38/11 ,  A61K31/196 ,  A61K31/7088

摘要： A composition for treating Fragile X syndrome in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.

公开(公告)号：US10183029B2

公开(公告)日：2019-01-22

申请号：US15408256

申请日：2017-01-17

申请人： Ferring B.V.

发明人： Joan-Carles Arce

IPC分类号： A61B17/435 ,  A61K31/57 ,  A61K31/404 ,  A61K38/11 ,  A61K38/12 ,  A61K9/00 ,  A61K45/06 ,  A61K31/4045 ,  A61K31/565

摘要： The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.

公开(公告)号：US20180369320A1

公开(公告)日：2018-12-27

申请号：US15400535

申请日：2017-01-06

申请人： Serenity Pharmaceuticals LLC

发明人： Seymour Fein

IPC分类号： A61K38/11 ,  A61K9/00 ,  A61M15/08 ,  A61M11/00 ,  A61M11/06

摘要： Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.

公开(公告)号：US20180325990A1

公开(公告)日：2018-11-15

申请号：US16044117

申请日：2018-07-24

申请人： Par Pharmaceutical, Inc.

发明人： Matthew Kenney ,  Vinayagam Kannan

IPC分类号： A61K38/11 ,  A61K47/10 ,  G01N30/74 ,  A61K47/26 ,  A61K47/12 ,  A61K9/00 ,  A61K47/02 ,  A61K45/06 ,  A61K31/045 ,  A61K9/08 ,  G01N30/02

CPC分类号： A61K38/11 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/045 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  G01N30/74 ,  G01N2030/027

摘要： Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

公开(公告)号：US20180325987A1

公开(公告)日：2018-11-15

申请号：US16044100

申请日：2018-07-24

申请人： Par Pharmaceutical, Inc.

发明人： Matthew Kenney ,  Vinayagam Kannan

IPC分类号： A61K38/11 ,  A61K47/10 ,  G01N30/74 ,  A61K47/26 ,  A61K47/12 ,  A61K9/00 ,  A61K47/02 ,  A61K45/06 ,  A61K31/045 ,  A61K9/08 ,  G01N30/02

CPC分类号： A61K38/11 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/045 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  G01N30/74 ,  G01N2030/027

摘要： Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

公开(公告)号：US20180289769A1

公开(公告)日：2018-10-11

申请号：US15811384

申请日：2017-11-13

申请人： Serenity Pharmaceuticals, LLC

发明人： Seymour H. Fein ,  Samuel Herschkowitz

IPC分类号： A61K38/11 ,  A61K31/426 ,  A61K9/00 ,  A61K45/06 ,  A61K38/08 ,  A61K47/08

摘要： The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.

公开(公告)号：US20180280469A1

公开(公告)日：2018-10-04

申请号：US15881123

申请日：2018-01-26

申请人： Ferring B.V.

发明人： Anders NILSSON ,  Hans LINDNER ,  Jørgen WITTENDORFF

IPC分类号： A61K38/11 ,  A61K47/42 ,  A61K47/26 ,  A61K47/12 ,  A61K38/12 ,  A61K38/08

CPC分类号： A61K38/11 ,  A61K9/0056 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2063 ,  A61K9/2095 ,  A61K38/08 ,  A61K38/12 ,  A61K47/12 ,  A61K47/26 ,  A61K47/42

摘要： Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

公开(公告)号：US10080768B2

公开(公告)日：2018-09-25

申请号：US15487818

申请日：2017-04-14

申请人： Transdermal Biotechnology, Inc.

发明人： Nicholas V. Perricone

IPC分类号： A61K33/00 ,  A61K38/22 ,  A61K38/28 ,  A61K38/06 ,  A61K47/48 ,  A61K9/06 ,  A61K9/00 ,  A61K9/127 ,  A61K38/00 ,  A61K38/11 ,  A61K38/34

CPC分类号： A61K33/00 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/127 ,  A61K38/00 ,  A61K38/06 ,  A61K38/066 ,  A61K38/095 ,  A61K38/2271 ,  A61K38/28 ,  A61K38/34 ,  A61K47/544 ,  A61K2300/00

摘要： The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

公开(公告)号：US20180250357A1

公开(公告)日：2018-09-06

申请号：US15880697

申请日：2018-01-26

申请人： Ferring B.V.

发明人： Bjarke M. Klein ,  Jens Peter Norgaard ,  Brad Shumel

IPC分类号： A61K38/11

摘要： The present disclosure is directed to gender, age, and dose effects of desmopressin on reducing nocturnal voids, increasing an initial period of undisturbed sleep, and/or reducing nocturnal urine volume.

公开(公告)号：US10028994B2

公开(公告)日：2018-07-24

申请号：US15487566

申请日：2017-04-14

申请人： Transdermal Biotechnology, Inc.

发明人： Nicholas V. Perricone

IPC分类号： A61K33/00 ,  A61K38/06 ,  A61K9/00 ,  A61K38/34 ,  A61K38/11 ,  A61K47/10 ,  A61K9/127

摘要： The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.